Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells
Prostate cancer (PC) is one of the most frequently diagnosed cancers and a leading cause of cancer-related deaths in Western society. Current PC therapies prevalently target the functions of androgen receptor (AR) and may only be effective within short time periods, beyond which the majority of PC p...
Saved in:
Main Authors: | Valentina Rossi (Author), Erika Di Zazzo (Author), Giovanni Galasso (Author), Caterina De Rosa (Author), Ciro Abbondanza (Author), Antonio A. Sinisi (Author), Lucia Altucci (Author), Antimo Migliaccio (Author), Gabriella Castoria (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corrigendum: Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cells
by: Valentina Rossi, et al.
Published: (2024) -
A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
by: Golor G, et al.
Published: (2012) -
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
by: Wolin EM, et al.
Published: (2015) -
Patients' satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
by: Christina Darden, et al.
Published: (2021) -
Somatostatin in inflammatory bowel disease
by: J. D. Van Bergeijk, et al.
Published: (1997)